A Phase Ib/II Clinical Trial to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of PM8002 Injection Combined With PM1009 Injection in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Latest Information Update: 19 Dec 2024
Price :
$35 *
At a glance
- Drugs PM-8002 (Primary) ; Atezolizumab; Bevacizumab; PM-1009
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biotheus
- 16 Dec 2024 Planned initiation date changed from 1 Oct 2024 to 1 Dec 2024.
- 06 Sep 2024 New trial record